

**Diagnostic value of the copper/zinc  
ratio in both serum and tissue in  
Hepatocellular carcinoma**

Thesis  
submitted for  
partial fulfillment of M.Sc. degree  
in Internal Medicine

By  
***Ahmed el Saady Khayyal***  
*M.B.B.Ch*

**Supervisors:**

**Prof.Dr Osama Abo El Fotoh El Sayed**  
Prof. of Internal Medicine Ain-Shams University

**Dr.Magdy Galal Abd El Rahman**  
Ass. Prof. of Internal Medicine Ain-Shams  
University

**Dr.Hosam Abd El Aziz Mahmoud**  
Lecturer of Internal Medicine Ain-Shams  
University

**Ain-Shams University**  
**2005**

# Acknowledgement

*First and foremost thanks to GOD, the most merciful. I would like to dedicate this work to the memory of my father Prof. Dr. EL Saady khayyal who was my guide ,my tutor, my support and to whom I owe all my success and achievements.*

*I wish to express my deep appreciation and sincere gratitude to Prof. Dr. Osama Abo EL Fotoh, continuous help, patience and guidance. He has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor for me to work under his supervision.*

*I wish to express my supreme gratitude to Dr. Magdy Galal for his kind assistance, supervision, continuous encouragement and for being kind enough to follow closely every step in the whole work.*

*With great pleasure, I would like to offer too much greetings to the active and faithful Dr. Hosam El-Din Abdel-Aziz for his advice, directions and revision of the whole study.*

*Special thanks to my colleague Dr. Yehia Mekiah for his sincere help .*

*To my Family , friends and colleagues who helped me and supported me all the way.*

**Ahmed El  
Saady  
2005**



# CONTENTS

Acknowledgement .....	I
Contents .....	II
List of tables .....	III
List of figures .....	VII
List of abbreviations .....	X

<b>_ Introduction .....</b>	<b>1</b>
<b>- Aim of the work .....</b>	<b>4</b>
<b>- Review of literature</b>	
<b>Chapter (1):Zinc .....</b>	<b>5</b>
<b>Chapter (2): Copper .....</b>	<b>17</b>
<b>Chapter (3): Hepatocellular carcinoma .....</b>	<b>38</b>
<b>- Patients and Methods .....</b>	<b>114</b>
<b>- Results .....</b>	<b>122</b>
<b>- Discussion .....</b>	<b>156</b>
<b>- Summary and Conclusion .....</b>	<b>162</b>
<b>- Recommendations .....</b>	<b>164</b>
<b>- References .....</b>	<b>165</b>
<b>- Arabic summary</b>	

## List of Abbreviations

AFB1	: Aflatoxin B1.
AFP	: Alpha fetoprotein.
ALP	: Alkaline phosphatase .
ALT	: Alanine transferase.
BMD	: Bone mineral density.
CHD	: Coronary heart disease .
CLD	: Chronic liver disease.
CT	: Computed tomographic scan.
Cu	: Copper .
DN	: Dysplastic nodules .
DNA	: Deoxy ribonucleic acid.
EASL	:European Association for the Study of the liver.
FNB	: Food and Nutrition Board .
HBc-Ag	: Hepatitis B core antigen .
HBs-Ag	: Hepatitis B surface antigen.
HBV	: Hepatitis B virus.
HCC	: Hepatocellular carcinoma.
HCV	: Hepatitis C virus.
HH	: Hereditary haemochromatosis.
LDL	: Low Density Lipoprotein
LOH	: Loss of heterozygosity.
mcg	: Microgram.
mg	: Milligram.
mm	: Millimeter.

PAI	: Percutaneous acetic acid injection.
PEI	: Percutaneous ethanol injection.
RDA	: Recommended daily allowance.
RTFA	: Radio frequency thermal ablation.
RNA	: Ribonucleic acid.
SOD	: Superoxide dismutase.
U/S	: Ultrasound
Zn	: Zinc.

## **List of Figures**

<b>Num</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Different grades of dysplastic nodules	65
<b>2</b>	Stromal invasion in Well-differentiated early-stage HCCs.	70
<b>3</b>	Gross picture of advanced HCC.	74
<b>4</b>	Treatment of HCC.	96
<b>5</b>	Experimental HCC therapies.	105
<b>6</b>	Primary HCC prevention.	106
<b>7</b>	Secondary HCC prevention.	110
<b>8</b>	Comparison between CLD and HCC group as regards ESR	144
<b>9</b>	Comparison between CLD and HCC group as regards Alpha-fetoprotein .	145
<b>10</b>	Comparison between Control, CLD and HCC groups as regards serum Copper levels.	146
<b>11</b>	Comparison between Control, CLD and HCC groups as regards serum Zinc levels.	147

<b>12</b>	Comparison between Control, CLD and HCC groups as regards serum copper-Zinc ratio.	<b>148</b>
<b>13</b>	Comparison between CLD and HCC groups as regards tissue Copper levels.	<b>149</b>
<b>14</b>	Comparison between CLD and HCC groups as regards tissue Copper levels.	<b>150</b>
<b>15</b>	Comparison between CLD and HCC groups as regards tissue Copper / Zinc ratio	<b>151</b>
<b>16</b>	Correlation between tissue copper and size of focal lesion.	<b>152</b>
<b>17</b>	Correlation between tissue copper/ zinc ratio and size of focal lesion.	<b>153</b>
<b>18</b>	Correlation between serum copper and AFP.	<b>154</b>
<b>19</b>	Correlation between serum zinc and AFP.	<b>155</b>



## **List of Tables**

Number	Title	Page
1	Recommended Dietary Allowance for copper	26
2	Copper content of food	33
3	Tolerable Upper Intake Level (UL) for Copper	36
4	Diagnostic criteria for HCC according to the Barcelona EASL conference.	79
5	TNM Staging of HCC	81
6	The Barcelona Clinic Liver Cancer classification staging of patients with HCC.	84
7	Okuda HCC staging	85
8	Comparison between HCC and CLD groups as regards age.	124
9	Comparison between HCC and CLD groups as regards sex	125
10	Comparison between CLD and HCC group as regards	126

	History	
11	Comparison between CLD and HCC group as regards Clinical examination	127
12	Comparison between CLD and HCC group as regards Liver function tests, Renal functions and CBC.	128
13	Comparison between CLD and HCC group as regards hepatitis markers.	129
14	comparison between CLD and HCC group as regards ESR	130
15	Comparison between CLD and HCC group as regards Alpha-fetoprotein .	131
16	Comparison between Control and CLD groups, Control and HCC groups ,CLD and HCC groups as regards serum Copper levels. .	132
17	Comparison between Control and CLD groups, Control and HCC groups ,CLD and HCC groups as regards serum Zinc levels.	133

18	Comparison between Control and CLD groups, Control and HCC groups ,CLD and HCC groups as regards serum Zinc levels.	134
19	Comparison between CLD and HCC group as regards Liver tissue copper.	135
20	Comparison between CLD and HCC group as regards Liver tissue zinc .	136
21	Comparison between CLD and HCC group as regards Liver tissue copper- zinc ratio .	137
22	Comparison between different classes of patients of CLD group according to Child - Pugh classification as regards serum copper, serum zinc, serum copper-zinc ratio, tissue copper, tissue zinc and tissue copper-zinc ratio.	138
23	Shows comparison between different classes of patients of HCC group according to Child - Pugh classification as	139

	regards serum copper, serum zinc, serum copper-zinc ratio, tissue copper, tissue zinc and tissue copper-zinc ratio.	
24	Correlation between largest diameter of hepatic tumor and serum copper, serum zinc, serum copper-zinc ratio.	140
25	Correlation between largest diameter of hepatic tumor and liver tissue copper, liver tissue zinc, liver tissue copper-zinc ratio.	141
26	Correlation between Alfa-fetoprotein and serum copper, serum zinc, serum copper-zinc ratio.	142
27	Correlation between Alfa-fetoprotein and liver tissue copper, liver tissue zinc, liver tissue copper-zinc ratio.	143

---

***Aim Of The Work***

Our study aimed to measure Copper , Zinc and Copper / Zinc ratio in cases of HCC and liver cirrhosis patients compared to normal controls to find out the possible value of these electrolytes as markers for prediction of HCC development in patients with liver cirrhosis .

## *Introduction*

Hepatocellular carcinoma (HCC) is a major cause of death in patients with chronic liver disease .Worldwide , HCC is estimated to cause between 250,000 and 1 million deaths annually (*Duvoux ,1998*).

In cirrhotic patients, the incidence of HCC annually has been reported to be between 2% and 7% (*Kountouras and Lygidakis , 2000*).

To improve the prognosis of HCC, it is important to detect its presence as early as possible . Thus , screening for HCC is widely believed to be an effective form of secondary prevention . Screening studies have shown that it is possible to find small lesions that may be resectable (*Gambarin-Gelwan et al., 2000* ).

The standard recommended screening tests for periodic follow up examinations are ultrasound (U/S) and alpha fetoprotein (AFP) . Both tests have significant false positive and false negative rates . Moreover , AFP determination is considered to be insufficient for early recognition of small HCC

## Introduction

---

because many patients with small masses have low levels of AFP and because serum levels of AFP are also elevated in benign liver disease (*Bayati et al., 1998*).

A greater problem is the finding of suspicious masses on U/S examination which require intensive investigation but turn out not to be HCC .therefore, other potentially useful screening tests are required in current clinical practice .

Hypozincemia, marked hypercupremia have been reported in patients with digestive (*Beno et al., 2000*), hepatic (*Masaaki et al., 2000* ), breast (*Yucel et al.,1994* ), lung (*Ren et al., 2000*), hematological malignancy (*Sun et al., 2000*).

Zinc and copper have been recognized as playing an important role as cofactors of superoxide dismutase.This enzyme protects cells against free radicals produing agents that might be involved in initiating neoplastic process (*Griglo et al., 1998* )

Zinc plays an important role as a cofactor of superoxide dismutase enzyme which protects cells against free radicals that might play a role in initiating neoplastic process (*Wu et al., 1998*).